Addpharma Inc. clinical trials

Acquired by Yuhan Corporation, 2018 · source ↗

The registry lists 58 studies whose lead sponsor is Addpharma Inc.. 25 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 58. List all 58 → · All Yuhan Corporation studies →

• A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination TherapyNot yet recruitingNCT07816198Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236BNot yet recruitingNCT07730567Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy AdultsNot yet recruitingNCT07717775Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male VolunteersNot yet recruitingNCT07722871Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsNot yet recruitingNCT07717749Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male VolunteersNot yet recruitingNCT07715305Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy AdultsNot yet recruitingNCT07618845Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231CNot yet recruitingNCT07590167Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the KneeNot yet recruitingNCT07550231Phase 2

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232Not yet recruitingNCT07538466Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy AdultsNot yet recruitingNCT07521241Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsNot yet recruitingNCT07476157Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male SubjectsRecruitingNCT07444385Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy AdultsNot yet recruitingNCT07385248Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'RecruitingNCT07385235Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231CNot yet recruitingNCT07312773Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322Not yet recruitingNCT07312799Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117ANot yet recruitingNCT07152873Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• The Food Effect on PK Characteristics and Safety Profiles of PA-111Not yet recruitingNCT06976489Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111ARecruitingNCT06932705Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120ANot yet recruitingNCT06916130Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284RecruitingNCT06884098Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-218RecruitingNCT05400317Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227BRecruitingNCT06441630Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Phase III Study to Evaluate the Efficacy and Safety of AD-209RecruitingNCT06348576Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282CompletedNCT06747936Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-224CompletedNCT06291207Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male VolunteersCompletedNCT07103278Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult VolunteersCompletedNCT07495514Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227BCompletedNCT06884085Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'CompletedNCT06902818Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282CompletedNCT06858865Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-223CompletedNCT06052748Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Assess the Safety and Pharmacokinetics of AD-104-ACompletedNCT05703282Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121CompletedNCT06025773Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022CompletedNCT06448962Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-209CompletedNCT05631990Phase 2

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-208CompletedNCT04825561Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK, PD and Safety of the AD-214 and AD-2141CompletedNCT05062876Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221ACompletedNCT05131997Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221BCompletedNCT05202405Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131CompletedNCT04690868Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091CompletedNCT05128591Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132CompletedNCT04755985Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK, PD and Safety of the AD-214-02 and RabeprazoleCompletedNCT04622358Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Determining the Optimal Dose of AD-209 in Patients With Essential HypertensionCompletedNCT04218552Phase 2

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• A Study to Compare PK, PD and Safety of the AD-214 10/600mg and RabeprazoleCompletedNCT04494243Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102CompletedNCT04600284Phase 1

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/AmlodipineCompletedNCT04158076Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation

• Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and TelmisartanCompletedNCT03872232Phase 3

  Sponsor listed in the registry: Addpharma Inc. · First submitted after Addpharma Inc. became part of Yuhan Corporation